Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74


Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.

Cavallari LH, Obeng AO.

Interv Cardiol Clin. 2017 Jan;6(1):141-149. doi: 10.1016/j.iccl.2016.08.010. Review.


Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.

Sridharan K, Kataria R, Tolani D, Bendkhale S, Gogtay NJ, Thatte UM.

Indian J Pharmacol. 2016 Jul-Aug;48(4):350-354.


The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity.

Lauschke VM, Ingelman-Sundberg M.

Int J Mol Sci. 2016 Oct 12;17(10). pii: E1714. Review.


Clinical Application of Pharmacogenetics: Where are We Now?

van Schaik RH; IFCC Task Force on Pharmacogenetics: Prof. Dr. Maurizio Ferrari (IT), Prof. Dr. Michael Neumaier (GER), Prof. Dr. Munir Pirmohamed (UK), Prof. Dr. Henk-Jan Guchelaar (NL), Prof. Dr. Ron van Schaik (NL)..

EJIFCC. 2013 Feb 21;24(3):105-12.


Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome.

Yan Y, Wang X, Fan JY, Nie SP, Raposeiras-Roubín S, Abu-Assi E, Henriques JP, D'Ascenzo F, Saucedo J, González-Juanatey JR, Wilton SB, Kikkert WJ, Nuñez-Gil I, Ariza-Sole A, Song XT, Alexopoulos D, Liebetrau C, Kawaji T, Moretti C, Huczek Z, Fujii T, Correia LC, Kawashiri MA, Kedev S.

J Geriatr Cardiol. 2016 Mar;13(3):209-17. doi: 10.11909/j.issn.1671-5411.2016.03.007.


Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response.

Liu XL, Jia QJ, Wang LN, Liu ZM, Liu H, Duan XC, Lyu XM.

Med Sci Monit. 2016 Jan 29;22:310-5.


Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.

Khalil BM, Shahin MH, Solayman MH, Langaee T, Schaalan MF, Gong Y, Hammad LN, Al-Mesallamy HO, Hamdy NM, El-Hammady WA, Johnson JA.

Clin Transl Sci. 2016 Feb;9(1):23-8. doi: 10.1111/cts.12383.


Physician response to implementation of genotype-tailored antiplatelet therapy.

Peterson JF, Field JR, Unertl KM, Schildcrout JS, Johnson DC, Shi Y, Danciu I, Cleator JH, Pulley JM, McPherson JA, Denny JC, Laposata M, Roden DM, Johnson KB.

Clin Pharmacol Ther. 2016 Jul;100(1):67-74. doi: 10.1002/cpt.331.


CYP2C19 drug-drug and drug-gene interactions in ED patients.

Flaten HK, Kim HS, Campbell J, Hamilton L, Monte AA.

Am J Emerg Med. 2016 Feb;34(2):245-9. doi: 10.1016/j.ajem.2015.10.055.


Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study.

Nelveg-Kristensen KE, Busk Madsen M, Torp-Pedersen C, Køber L, Egfjord M, Berg Rasmussen H, Riis Hansen P.

PLoS One. 2015 Dec 3;10(12):e0144195. doi: 10.1371/journal.pone.0144195.


Early definite stent thrombosis with everolimus-eluting stents.

Naito R, Miyauchi K, Konishi H, Tsuboi S, Okazaki S, Daida H.

Clin Case Rep. 2015 Oct;3(10):854-7. doi: 10.1002/ccr3.364.


Bivalirudin plus loading dose of cilostazol-based triple-antiplatelet in treatment of non-ST-elevation myocardial infarction following percutaneous coronary intervention.

Wang M, Zhang G, Wang Y, Zhou K, Liu T, Zhang Y, Guo A, An Y, Zhang X, Li Y.

Ther Clin Risk Manag. 2015 Sep 28;11:1469-73. doi: 10.2147/TCRM.S86799.


Pharmacogenetics: Using Genetic Information to Guide Drug Therapy.

Chang KL, Weitzel K, Schmidt S.

Am Fam Physician. 2015 Oct 1;92(7):588-94.


Cardiovascular pharmacogenomics: current status and future directions.

Roden DM.

J Hum Genet. 2016 Jan;61(1):79-85. doi: 10.1038/jhg.2015.78. Review.


The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Yang Y, Lewis JP, Hulot JS, Scott SA.

Expert Opin Drug Metab Toxicol. 2015;11(10):1599-617. doi: 10.1517/17425255.2015.1068757. Review.


Routine genotyping of patients on clopidogrel: Why the resistance?

Karthikeyan G.

Indian Heart J. 2015 Mar-Apr;67(2):93-4. doi: 10.1016/j.ihj.2015.04.008. No abstract available.


Genotype-based clinical trials in cardiovascular disease.

Pereira NL, Sargent DJ, Farkouh ME, Rihal CS.

Nat Rev Cardiol. 2015 Aug;12(8):475-87. doi: 10.1038/nrcardio.2015.64. Review.

Items per page

Supplemental Content

Support Center